The impact of adding taxanes to gemcitabine and platinum chemotherapy for the first-line therapy of advanced or metastatic urothelial cancer: A systematic review and meta-analysis

European Urology

Volumn 69, Issue 4, 2016, Pages 624-633

  Giannatempo, Patrizia ^a   Pond, Gregory R ^b   Sonpavde, Guru ^c   Raggi, Daniele ^a   Naik, Gurudatta ^c   Galsky, Matthew D ^d   Bellmunt, Joaquim ^e   Necchi, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

First line therapy; Meta analysis; Systemic therapy; Taxanes; Urothelial carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM DERIVATIVE; TAXOID;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; META ANALYSIS; METASTASIS; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK FACTOR; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MULTIVARIATE ANALYSIS; PLATINUM COMPOUNDS; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84959558265     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.09.051     Document Type: Review

References (50)

1. W. Abida, D.F. Bajorin, and J.E. Rosenberg First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients Hematol Oncol Clin North Am 29 2015 319 328
2. G. Sonpavde, M.D. Galsky, and N.J. Vogelzang First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol 28 2010 e441 e442
3. G. Sonpavde, D. Watson, M. Tourtellot, and et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community Clin Genitourin Cancer 10 2012 1 5
4. M.D. Galsky, G.J. Chen, W.K. Oh, and et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advancd urothelial carcinoma Ann Oncol 23 2012 406 410
5. M.D. Galsky, N.M. Hahn, J.E. Rosenberg, and et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy J Clin Oncol 29 2011 2432 2438
6. J.A. McCaffrey, S. Hilton, M. Mazumdar, and et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 16 1997 1853 1857
7. B.J. Roth, R. Dreicer, L.H. Einhorn, and et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 12 1994 2264 2270
8. J. Bellmunt, H. von der Maase, G.M. Mead, and et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987 J Clin Oncol 30 2012 1107 1113
9. H. von der Maase, L. Andersen, L. Crinò, and et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial Ann Oncol 10 1999 1 5
10. D. Kaufman, D. Raghavan, M. Carducci, and et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921 1927
11. M.J. Moore, E.W. Winquist, N. Murray, and et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 17 1999 2876 2881
12. M. Hussain, S. Daignault, N. Agarwal, and et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without ceuximab in patients with advanced urothelial carcinoma Cancer 120 2014 2684 2693
13. A. Bamias, L.A. Moulopoulos, A. Koutras, and et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group Cancer 106 2006 297 303
14. R. Morales-Barrera, J. Bellmunt, C. Suarez, and et al. Cisplatin and gemcitabine every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function Eur J Cancer 48 2012 1816 1821
15. J. Bellmunt, R. de Wit, J. Albanell, and J. Baselga A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer Eur J Cancer 37 2001 2212 2215
16. J. Carles, M. Nogué, M. Domènech, and et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function Oncology 59 2000 24 27
17. B. Hoschke, M. May, M. Seehafer, and C. Helke Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium Int J Urol 11 2004 461 466
18. H. Khaled, M.E. Emara, and R.M. Gaafar Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial Urol Oncol 26 2008 133 136
19. A. Baitar, M. De Vos, A. Vandebroeck, and D. Schrijvers Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: a phase II study J Ger Oncol 2 2011 31 35
20. S. Krege, H. Rexer, F. vom Dorp, and et al. Prospective randomizd double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urohelial cancer: SUSE (AUO-AB 31/05) BJU Int 113 2014 429 436
21. V. Lorusso, L. Manzione, F. De Vita, and et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of teh urinary tract: a phase II multicenter trial J Urol 164 2000 53 56
22. A. Bamias, G. Lainakis, E. Kastritis, and et al. Biweekly carbopaltin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment Oncology 73 2007 290 297
23. H. Linardou, G. Aravantinos, E. Efstathiou, and et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group Urology 64 2004 479 484
24. M. Nogué-Aliguer, J. Carles, A. Arrivi, and et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy Cancer 97 2003 180 186
25. E. Hudson, and J.F. Lester Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single-centre experience and review of the literature Eur J Cancer Care 19 2010 324 328
26. C. Shannon, C. Crombie, A. Brooks, and et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features Ann Oncol 12 2001 947 952
27. N. Xu, X.C. Zhang, J.P. Xiong, and et al. A phase II trial of gemcitabine plus cisplatin in advanced transitional cell carcinoma of the urothelium BMC Cancer 7 2007 98
28. L. Dogliotti, G. Cartenì, S. Siena, and et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial Eur Urol 52 2007 134 141
29. J.H. Park, S.W. Lee, H.S. Kim, and et al. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract Cancer Chemother Pharmacol 71 2013 1033 1039
30. T.H. Ecke, P. Bartel, S. Koch, J. Ruttloff, and F. Theissig Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium Oncol Rep 16 2006 1381 1388
31. J.D. Hainsworth, A.A. Meluch, S. Litchy, and et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium Cancer 103 2005 2298 2303
32. M. Hussain, U. Vaishampayan, W. Du, B. Redman, and D.C. Smith Combination paclitaxel, carboplatin, and gemcitabine is an active treatment in advanced urothelial cancer J Clin Oncol 19 2001 2527 2533
33. V. Lorusso, E. Crucitta, N. Silvestris, and et al. Randomized, open-label, phase II trial of paclitaxel, gemcitabine, and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium Oncol Rep 13 2005 283 287
34. D. Pectasides, J. Glotsos, N. Bountouroglou, and et al. Weekly docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial Ann Oncol 13 2002 243 250
35. I. Boukovinas, N. Androulakis, N. Kentepozidis, and et al. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) Cancer Chemother Pharmacol 69 2012 351 356
36. H. von der Maase, S.W. Hansen, J.T. Roberts, and et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
37. A. Bamias, U. Dafni, A. Karadimou, and et al. Prospective, open-label, rancomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) Ann Oncol 24 2013 1011 1017
38. C.N. Sternberg, I.A. Skoneczna, D. Castellano, and et al. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB) Oncology 85 2013 208 215
39. M. De Santis, J. Bellmunt, G. Mead, and et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 J Clin Oncol 30 2012 191 199
40. A. Liberati, D.G. Altman, J. Tetzlaff, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 339 2009 b2700
41. J. Bellmunt, and D.P. Petrylak New therapeutic challenges in advanced bladder cancer Semin Oncol 39 2012 598 607
42. Y.J. Ko, C.M. Canil, S.D. Mukherjee, and et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study Lancet Oncol 14 2013 769 776
43. S. Alva, Daignault, D.C. Smith, and M. Hussain Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first-line therapy of advanced urothelial carcinoma Invest New Drugs 32 2014 188 194
44. T.E. Hutson, S. Vukelja, D. Atienza, and et al. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium Invest New Drugs 26 2008 151 158
45. D.I. Quinn, N. Ruel, P. Twardowski, and et al. Eribulin in advanced urothelial cancer (AUC) patients (pts): a California Cancer Consortium trial - NCI/CTEP 7435 J Clin Oncol 33 suppl; abstr 4504 2015
46. N.J. Vogelzang, P. Conkling, I. Duran, and et al. Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: phase Ib results J Clin Oncol 30 suppl 5; abstr 273 2012
47. N.M. Hahn, W.M. Stadler, ZonRT, and et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75 J Clin Oncol 29 2011 1525 1530
48. J. Bellmunt, B.J. Eigl, E. Senkus-Konefka, and et al. First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: the international Borealis-1 trial J Clin Oncol 33 suppl; abstr 4503 2015
49. S. Oudard, S. Culine, Y. Vano, and et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 Eur J Cancer 51 2015 45 54
50. T. Powles, J.P. Eder, G.D. Fine, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562